These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 10925968

  • 1. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS.
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [Abstract] [Full Text] [Related]

  • 2. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [Abstract] [Full Text] [Related]

  • 3. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):527-38. PubMed ID: 15339324
    [Abstract] [Full Text] [Related]

  • 4. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL.
    Rheumatology (Oxford); 2003 Nov 01; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL, Aisenberg J, Lanza F, Schwartz H, Sands GH, Berger MF, Pan S.
    Clin Ther; 2006 Mar 01; 28(3):340-51. PubMed ID: 16750449
    [Abstract] [Full Text] [Related]

  • 6. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.
    Am J Med; 2005 Nov 01; 118(11):1271-8. PubMed ID: 16271912
    [Abstract] [Full Text] [Related]

  • 7. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G, SUCCESS-I Investigators.
    Am J Med; 2006 Mar 01; 119(3):255-66. PubMed ID: 16490472
    [Abstract] [Full Text] [Related]

  • 8. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.
    JAMA; 2000 Sep 13; 284(10):1247-55. PubMed ID: 10979111
    [Abstract] [Full Text] [Related]

  • 9. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
    Soni P, Shell B, Cawkwell G, Li C, Ma H.
    Curr Med Res Opin; 2009 Aug 13; 25(8):1841-51. PubMed ID: 19530981
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 13; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 13. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

  • 14. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
    Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ.
    N Engl J Med; 2002 Dec 26; 347(26):2104-10. PubMed ID: 12501222
    [Abstract] [Full Text] [Related]

  • 15. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.
    Pharmacoepidemiol Drug Saf; 2007 Apr 26; 16(4):366-76. PubMed ID: 16897817
    [Abstract] [Full Text] [Related]

  • 16. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.
    J Rheumatol; 2000 Aug 26; 27(8):1876-83. PubMed ID: 10955327
    [Abstract] [Full Text] [Related]

  • 17. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Eisen GM, Goldstein JL, Hanna DB, Rublee DA.
    Aliment Pharmacol Ther; 2005 Mar 01; 21(5):591-8. PubMed ID: 15740543
    [Abstract] [Full Text] [Related]

  • 18. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK, Castellsague J, Walker AM.
    Pharmacoepidemiol Drug Saf; 2008 Oct 01; 17(10):982-8. PubMed ID: 18711705
    [Abstract] [Full Text] [Related]

  • 19. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
    Cheung R, Cheng TT, Dong Y, Lin HY, Lai K, Lau CS, Feng H, Parsons B.
    Int J Rheum Dis; 2010 May 01; 13(2):151-7. PubMed ID: 20536600
    [Abstract] [Full Text] [Related]

  • 20. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR, Essex MN, Zhang R.
    Curr Med Res Opin; 2011 Jul 01; 27(7):1359-66. PubMed ID: 21561397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.